Dramatic advances in the fields of biochemistry, cell and molecular biology, genetics, biomedical engineering and materials science have given rise to the remarkable new cross-disciplinary field of tissue engineering. Tissue engineering uses synthetic or naturally derived, engineered biomaterials to replace damaged or defective tissues, such as bone, skin, and even organs.
Organogenesis, Inc. will have a substantial presence at the 23rd Annual Symposium on Advanced Wound Care and Wound Healing Society being held April 17-20 in Orlando, FL. Results from several clinical and scientific studies will be presented which will further the understanding of Organogenesis' bilayered living cellular construct technology.
It's illegal for health products with medical formulations to be accepted by the U.S. Food and Drug Administration without tests on animals ― a situation that has serious ethical and moral implications. New research in the field of tissue engineering by Prof. Amit Gefen of Tel Aviv University's Faculty of Engineering holds a promise that far fewer lab animals will be needed for the necessary experimental trials.
SANUWAVE Health, Inc., an emerging medical technology company focused on regenerative medicine, reports its financial results for the fourth quarter and full year ended December 31, 2009, and on its progress for the year.
Bioheart, Inc., announced today that Dr. Karl E. Groth, the Company's Chairman and CEO will speak at the 2010 Translational Regenerative Medicine Forum in Winston-Salem, North Carolina, on April 8. Dr. Groth will discuss Bioheart's cell therapies for Congestive Heart Failure.
A Worcester Polytechnic Institute research team has received a four-year, $1.4 million award from the National Institutes of Health to continue a groundbreaking study of arterial plaque. This research could lead to tools that will enable physicians to predict the likelihood of plaque rupture, which is responsible for most heart attacks and strokes.
Bone stem cells could in future be used instead of bone from donors as part of an innovative new hip replacement treatment, according to scientists at the University of Southampton.
Professor James Lorens and his team at the University of Bergen's Department of Biomedicine are using nanotechnology to study how to make cells form new blood vessels, both within the patient's body and in the laboratory. In the next phase the team will use this knowledge to investigate the molecular mechanisms that govern the progression of cancer.
Prof. Smadar Cohen, head of the University's Avram and Stella Goldstein-Goren Department of Biotechnology Engineering, has been awarded the prestigious Rappaport Prize for Excellence in Biomedical Research, an award totaling $100,000. The prize, given by Israel's Rappaport Foundation, is presented annually to a researcher whose research has either significantly advanced or has the potential to significantly advance any medical or biomedical field.
In an ongoing effort to mirror the ability of biological tissues to respond rapidly and appropriately to changing environments, scientists from the McGowan Institute for Regenerative Medicine have synthesized a single, multifunctional polymer material that can decontaminate both biological and chemical toxins. They described the findings recently in Biomaterials.
A team of McGill Chemistry Department researchers led by Dr. Hanadi Sleiman has achieved a major breakthrough in the development of nanotubes - tiny "magic bullets" that could one day deliver drugs to specific diseased cells.
ZenBio announce that they will be a commercial source for the popular murine 3T3-L1 cell line, which has been fundamental in metabolic disease research for 30 years.
RepRegen™, the ‘smart biomaterials’ company previously known as BioCeramic Therapeutics, announced today that data from an in vitro study has demonstrated that its patented Strontium-based bioactive glass platform promotes osteoblast cell activity and proliferation. If in vivo studies, which are currently underway, demonstrate similar results, then RepRegen believes its platform has the potential to significantly improve the repair and regeneration of hard-tissue, such as bone.
Entelos, Inc., a simulation and modeling company focused on human health, and RegeneMed, Inc., a tissue-based drug discovery and regenerative medicine company, announced today the release of iToxFX™.
Soluble Systems, LLC and the Skin and Wound Allograft Institute, a wholly owned subsidiary of LifeNet Health, have signed a noteworthy agreement to launch TheraSkin™, a biologically active human skin allograft designed to jumpstart healing in chronic and acute wounds.
University of Calgary chemistry professor David Cramb is a step closer to helping solve a complex problem in nanotechnology: the impact nanoparticles have on human health and the environment.
Injuries to joints and cartilage can have serious consequences, including osteoarthritis. Cartilage degeneration in joints is a widespread disease in Germany and worldwide. Prof. Dr. Prasad Shastri is an expert in tissue engineering (TE), tissue construction and tissue cultivation using the body's own cells. He is Professor of Biofunctional Macromolecular Chemistry at the Centre for Biological Signalling Studies (BIOSS), a Cluster of Excellence at the University of Freiburg, where he has been researching for the last year.
Clinical testing and development of novel therapies based on advances in tissue engineering and regenerative medicine that will one day enable the repair and replacement of diseased or damaged human muscle, bone, tendons, and ligaments depends on the availability of good animal models.
For the first time, scientists have performed a detailed long-term evaluation and comparison of two different types of pluripotent stem cells: human embryonic stem cells (hESC) and induced pluripotency stem cells (iPSC). Both cell types are believed to share equal characteristics, abilities and potential to differentiate into nearly 220 different cell types. However, hESC are isolated from early human embryos and iPSC are derived from reprogrammed adult somatic cells which makes them less controversial.
Health care companies that design and manufacture medical devices, equipment, and instruments can now help their technologists, engineers, and other employees conduct research more efficiently and effectively, resulting in greater cost savings and faster development times for new products.
Pluristem Therapeutics Inc. today announced that the results of a pre-clinical study in an animal model of ischemic stroke demonstrated that its PLacental eXpanded (PLX) cell therapy may be an effective treatment for this disorder.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.